Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis: Do the Known Risks Now Outweigh the Benefits?

Author： Lindelöf B.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.20, Iss.4, 1999-04, pp. : 289-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aluminium in Over-the-Counter Drugs: Risks Outweigh Benefits?

By Reinke C.M.  

Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. : 1011-1025

Adis International

Access to resources Recommend Favorite

Newer Biological Agents in the Treatment of Rheumatoid Arthritis: Do the Benefits Outweigh the Risks?

By Nurmohamed Michael T.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2035-2043

Adis International

Access to resources Recommend Favorite

Ipilimumab: will benefits outweigh risks in the eyes of the FDA?

By  

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

US seniors set to reap benefits?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 350, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

By Murray T Jock  

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 265-274

Informa Healthcare

Access to resources Recommend Favorite